These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35695019)

  • 1. Indications and effects of biological agents in the treatment of noninfectious uveitis.
    Li B; Yang L; Bai F; Tong B; Liu X
    Immunotherapy; 2022 Aug; 14(12):985-994. PubMed ID: 35695019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics in the Treatment of Uveitis.
    Dingerkus VLS; Becker MD; Doycheva D
    Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.
    Thomas AS
    Curr Opin Ophthalmol; 2019 May; 30(3):138-150. PubMed ID: 30844945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-anti TNFα biologic agents for noninfectious uveitis associated with systemic inflammatory diseases: a systematic review.
    Bitossi A; Mattioli I; Bettiol A; Palermo A; Malandrino D; Bacherini D; Virgili G; Giansanti F; Vannozzi L; Silvestri E
    Expert Rev Clin Immunol; 2023 May; 19(5):549-560. PubMed ID: 36939549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future treatments for Behçet's uveitis: road to remission.
    Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A
    Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor necrosis factor-α agents in noninfectious uveitis.
    Gueudry J; LeHoang P; Bodaghi B
    Dev Ophthalmol; 2012; 51():63-78. PubMed ID: 22517205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
    Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
    J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically engineered biological agents in the treatment of uveitis in patients with ankylosing spondylitis (clinical observations).
    Razumova IY; Godzenko AA
    Vestn Oftalmol; 2022; 138(3):68-72. PubMed ID: 35801883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
    Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
    Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
    [No Abstract]   [Full Text] [Related]  

  • 10. [The prospects of the biotherapy for refractory uveitis].
    Zheng YZ
    Zhonghua Yan Ke Za Zhi; 2016 Jul; 52(7):551-6. PubMed ID: 27531117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
    Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
    J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease.
    Sugita S; Kawazoe Y; Imai A; Yamada Y; Horie S; Mochizuki M
    Arthritis Res Ther; 2012 May; 14(3):R99. PubMed ID: 22546542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional immunosuppressive therapy in severe Behcet's Uveitis: the switch rate to the biological agents.
    Celiker H; Kazokoglu H; Direskeneli H
    BMC Ophthalmol; 2018 Oct; 18(1):261. PubMed ID: 30290779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor necrosis factor-α therapy in uveitis.
    Cordero-Coma M; Sobrin L
    Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease.
    Sugita S; Kawazoe Y; Imai A; Kawaguchi T; Horie S; Keino H; Takahashi M; Mochizuki M
    J Immunol; 2013 Jun; 190(11):5799-808. PubMed ID: 23630362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Eye and Behçet's disease].
    Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
    J Fr Ophtalmol; 2019 Jun; 42(6):626-641. PubMed ID: 31164292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis.
    Gupta S; Shyamsundar K; Agrawal M; Vichare N; Biswas J
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):203-222. PubMed ID: 35133890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biologics in uveitis].
    Feurer E; Bielefeld P; Saadoun D; Sève P
    Rev Med Interne; 2015 Feb; 36(2):107-16. PubMed ID: 25239400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.